Osteopenia Management

Initial Diagnostic Workup

The American College of Radiology recommends obtaining a DXA scan of the lumbar spine, total hip, and femoral neck as the gold standard for diagnosing osteopenia (T-score between -1.0 and -2.5) 1, 3
DXA provides the most accurate prediction of fracture risk and has been validated for absolute, relative, and lifetime fracture risk at multiple sites 3
Peripheral bone density testing may identify higher-risk patients but requires confirmation with central DXA 4

The American College of Radiology recommends initiating pharmacologic treatment when the 10-year probability of major osteoporotic fracture is ≥20% on FRAX 3, 2
The American College of Radiology also recommends initiating pharmacologic treatment when the 10-year probability of hip fracture is ≥3% on FRAX 3, 2
The American College of Radiology recommends treating patients with a history of low-trauma/fragility fracture, regardless of FRAX score or BMD 2

The American College of Internal Medicine recommends oral bisphosphonates as the first-line treatment for postmenopausal women and men ≥50 years meeting treatment thresholds 7, 2
The American College of Internal Medicine recommends alternative therapies, including intravenous bisphosphonates (zoledronic acid), denosumab, and raloxifene, for patients intolerant or with contraindications to oral bisphosphonates 7, 2, 6

The American College of Internal Medicine recommends calcium supplementation (1000-1200 mg/day) and vitamin D supplementation (600-800 IU/day) for all osteopenic patients 7, 2
The American College of Internal Medicine recommends weight-bearing exercise and resistance training to improve bone density and reduce fall risk 2
The American College of Internal Medicine recommends smoking cessation and limiting alcohol consumption to ≤2 drinks per day 1, 2

The American College of Internal Medicine recommends treating patients with bisphosphonates for 5 years initially 7
The American College of Internal Medicine recommends reassessing fracture risk and considering drug discontinuation in patients at low risk for fracture after 3-5 years of treatment 7

The American Medical Association notes that African-American women have higher average BMD than White women at any given age and lower fracture incidence, making them less likely to benefit from screening at younger ages 1, 4
The American Medical Association notes that Asian women may have lower BMD than White women but paradoxically lower fracture risk, suggesting BMD alone doesn't fully capture fracture risk across populations 1